Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Stine Braendegaard Whither; Gabor Liposits; Haifa Skuladottir; Eva Hofsli; Carl-Henrik Shah; Laurids Ostergaard Poulsen; Jesper Ryg; Pia Österlund; Åke Berglund; Camilla Qvortrup; Bengt Glimelius; Halfdan Sorbye; Per Pfeiffer

doi:10.1016/S2468-1253(19)30041-X

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

Stine Braendegaard Whither, Gabor Liposits, Haifa Skuladottir, Eva Hofsli, Carl-Henrik Shah, Laurids Ostergaard Poulsen, Jesper Ryg, Pia Österlund, Åke Berglund, Camilla Qvortrup, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	The Lancet gastroenterology & hepatology
Volume	4
Issue number	5
Pages (from-to)	376-388
Number of pages	13
ISSN	2468-1253
DOIs	https://doi.org/10.1016/S2468-1253(19)30041-X
Publication status	Published - May 2019
MoE publication type	A1 Journal article-refereed

Fields of Science

GERIATRIC ASSESSMENT
ELDERLY-PATIENTS
INTERNATIONAL SOCIETY
SCREENING TOOLS
PRODIGE 20
FEASIBILITY
CONSENSUS
3121 General medicine, internal medicine and other clinical medicine

Access to Document

10.1016/S2468-1253(19)30041-X

Cite this

Whither, S. B., Liposits, G., Skuladottir, H., Hofsli, E., Shah, C.-H., Poulsen, L. O., Ryg, J., Österlund, P., Berglund, Å., Qvortrup, C., Glimelius, B., Sorbye, H., & Pfeiffer, P. (2019). Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet gastroenterology & hepatology, 4(5), 376-388. https://doi.org/10.1016/S2468-1253(19)30041-X

@article{5f469ed1563443eeb27d657085a8ee84,

title = "Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial",

keywords = "GERIATRIC ASSESSMENT, ELDERLY-PATIENTS, INTERNATIONAL SOCIETY, SCREENING TOOLS, PRODIGE 20, FEASIBILITY, CONSENSUS, 3121 General medicine, internal medicine and other clinical medicine",

author = "Whither, {Stine Braendegaard} and Gabor Liposits and Haifa Skuladottir and Eva Hofsli and Carl-Henrik Shah and Poulsen, {Laurids Ostergaard} and Jesper Ryg and Pia {\"O}sterlund and {\AA}ke Berglund and Camilla Qvortrup and Bengt Glimelius and Halfdan Sorbye and Per Pfeiffer",

year = "2019",

month = may,

doi = "10.1016/S2468-1253(19)30041-X",

language = "English",

volume = "4",

pages = "376--388",

journal = "The Lancet gastroenterology & hepatology",

issn = "2468-1253",

publisher = "Elsevier Inc. ",

number = "5",

}

Whither, SB, Liposits, G, Skuladottir, H, Hofsli, E, Shah, C-H, Poulsen, LO, Ryg, J, Österlund, P, Berglund, Å, Qvortrup, C, Glimelius, B, Sorbye, H & Pfeiffer, P 2019, 'Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial', The Lancet gastroenterology & hepatology, vol. 4, no. 5, pp. 376-388. https://doi.org/10.1016/S2468-1253(19)30041-X

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. / Whither, Stine Braendegaard; Liposits, Gabor; Skuladottir, Haifa et al.
In: The Lancet gastroenterology & hepatology, Vol. 4, No. 5, 05.2019, p. 376-388.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9)

T2 - a randomised, open-label phase 2 trial

AU - Whither, Stine Braendegaard

AU - Liposits, Gabor

AU - Skuladottir, Haifa

AU - Hofsli, Eva

AU - Shah, Carl-Henrik

AU - Poulsen, Laurids Ostergaard

AU - Ryg, Jesper

AU - Österlund, Pia

AU - Berglund, Åke

AU - Qvortrup, Camilla

AU - Glimelius, Bengt

AU - Sorbye, Halfdan

AU - Pfeiffer, Per

PY - 2019/5

Y1 - 2019/5

KW - GERIATRIC ASSESSMENT

KW - ELDERLY-PATIENTS

KW - INTERNATIONAL SOCIETY

KW - SCREENING TOOLS

KW - PRODIGE 20

KW - FEASIBILITY

KW - CONSENSUS

KW - 3121 General medicine, internal medicine and other clinical medicine

U2 - 10.1016/S2468-1253(19)30041-X

DO - 10.1016/S2468-1253(19)30041-X

M3 - Article

SN - 2468-1253

VL - 4

SP - 376

EP - 388

JO - The Lancet gastroenterology & hepatology

JF - The Lancet gastroenterology & hepatology

IS - 5

ER -

Whither SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LO et al. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet gastroenterology & hepatology. 2019 May;4(5):376-388. doi: 10.1016/S2468-1253(19)30041-X